Generic placeholder image

Recent Patents on Biotechnology

Editor-in-Chief

ISSN (Print): 1872-2083
ISSN (Online): 2212-4012

Research Article

A Novel Cell-based In vitro Assay for Antiviral Activity of Interferons α, β, and γ by qPCR of MxA Gene Expression

Author(s): Mohamed A. Saber, Hend Okasha*, Fatma Khorshed and Safia Samir

Volume 15, Issue 1, 2021

Published on: 12 November, 2020

Page: [67 - 75] Pages: 9

DOI: 10.2174/1872208314666201112105053

Price: $65

Abstract

Background: Human MxA gene is related to the class of interferon (IFN)-stimulated genes (ISGs) that plays a role in antiviral resistance.

Objective: Implementation of standard curves obtained from designing a procedure for data processing in relative qPCR between MxA expression and interferon’s antiviral activity (IU/ml). These standard curves can be used to detect the antiviral activity of any new compound rapidly and safely.

Methods: To detect the optimum incubation time for maximum MxA gene expression in human peripheral blood mononuclear cells (PBMC), the isolated human PBMCs (1x106 cells) were incubated with a concentration of 1000 IU/ml of each IFN at different time intervals; 2 h, 4 h, 6 h, and 24 h post-treatment. A standard curve was performed for each IFN (α, β, and γ) at different concentrations (250, 500, 750, 1000, 1500, and 2000 IU/ml).

Results: As observed at 4 h incubation time of 1000 IU/ml concentration, IFN-γ provided a higher expression of MxA compared to IFN-α and IFN-β. Correlation analyses between IFN-α and IFN-β, IFN-β and IFN-γ were non-significant. However, there was a significant correlation between IFN-α and IFN-γ (p<0.01). Receiver operator characteristic (ROC) analysis revealed that cut-off values of IFN- γ, IFN-β, and IFN-α were 58.14 > 7.31 and > 3.33, respectively.

Conclusions: The relative expression of MxA is a biomarker for IFN-α, β, and γ, especially IFN-α. It has compiled and validated a standard curve-based protocol for PCR data processing. It shows that the standard curve is an easy alternative tool to assess antiviral activity. We revised all patents relating to the antiviral assays of the used interferons.

Keywords: PBMCs, MxA, antiviral, interferon-alpha, interferon-beta, interferon-gamma, qRT-PCR.

Graphical Abstract
[1]
Kang S, Brown HM, Hwang S. Direct antiviral mechanisms of interferon-gamma. Immune Netw 2018; 18(5): e33.
[http://dx.doi.org/10.4110/in.2018.18.e33] [PMID: 30402328]
[2]
Okasha H. Interferon and p53 tumor suppressor marker in hepatocellular carcinoma. Int J Pharm Res 2020; 12(2): 11-4.
[http://dx.doi.org/10.31838/ijpr/2020.12.02.0008]
[3]
Venkataraman S, Ahmad T, AbouHaidar MG, Hefferon KL. Virus-based rna silencing agents and virus-derived expression vectors as gene therapy vehicles. Recent Pat Biotechnol 2017; 11(2): 141-51.
[http://dx.doi.org/10.2174/1872208311666170301103722] [PMID: 28260520]
[4]
Majoros A, Platanitis E, Kernbauer-Hölzl E, Rosebrock F, Müller M, Decker T. Canonical and non-canonical aspects of JAK-STAT signaling: Lessons from interferons for cytokine responses. Front Immunol 2017; 8(29): 29.
[http://dx.doi.org/10.3389/fimmu.2017.00029] [PMID: 28184222]
[5]
Okasha H. Interferon and p53 tumor suppressor marker in hepatocellular carcinoma,” Int J Pharm Res 2020; 12(2): 11.
[http://dx.doi.org/10.31838/ijpr/2020.12.02.0008]
[6]
Green R, Ireton RC, Gale M Jr. Interferon-stimulated genes: new platforms and computational approaches. Mamm Genome 2018; 29(7-8): 593-602.
[http://dx.doi.org/10.1007/s00335-018-9755-6] [PMID: 29982912]
[7]
Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105(19): 7034-9.
[http://dx.doi.org/10.1073/pnas.0707882105] [PMID: 18467494]
[8]
Sadler A J, Williams B R G. "Interferon-inducible antiviral effectors,” Nat Rev Immunol 2008; 8(7): 559-68.
[http://dx.doi.org/10.1038/nri2314]
[9]
Mesev E V, LeDesma R A, Ploss A. “Decoding type I and III interferon signalling during viral infection,” Nat Microbiol 2019; 4(6): 914-24.
[http://dx.doi.org/10.1038/s41564-019-0421-x]
[10]
Jefferies CA. Regulating IRFs in IFN driven disease. Front Immunol 2019; 10(325): 325.
[http://dx.doi.org/10.3389/fimmu.2019.00325] [PMID: 30984161]
[11]
Vallittu AM, Erälinna JP, Ilonen J, Salmi AA, Waris M. MxA protein assay for optimal monitoring of IFN-β bioactivity in the treatment of MS patients. Acta Neurol Scand 2008; 118(1): 12-7.
[http://dx.doi.org/10.1111/j.1600-0404.2007.00968.x] [PMID: 18081914]
[12]
Pervolaraki K, Rastgou Talemi S, Albrecht D, et al. Bormann F, Bamford C, Mendoza JL, et al. Differential induction of interferon stimulated genes between type I and type III interferons is independent of interferon receptor abundance. PLoS Pathog 2018; 14(11): e1007420.
[http://dx.doi.org/10.1371/journal.ppat.1007420] [PMID: 30485383]
[13]
Shaker O, Ahmed A, Doss W, Abdel-Hamid M. MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients. J Viral Hepat 2010; 17(11): 794-9.
[http://dx.doi.org/10.1111/j.1365-2893.2009.01241.x] [PMID: 20002306]
[14]
Saber MA, Samir El-Naggar S, Hassanein MH, Barakat AB. “Role of Mxa and neutralizing antibodies in early response to interferon treatment in Hepatitis C Egyptian patients,” Eur J Biomed Pharm Sci 2020; 4(2): 84-94.
[15]
Ho M, Enders JF. Further studies on an inhibitor of viral activity appearing in infected cell cultures and its role in chronic viral infections. Virology 1959; 9(3): 446-77.
[http://dx.doi.org/10.1016/0042-6822(59)90135-7] [PMID: 14402114]
[16]
Riedhammer C, Halbritter D, Weissert R. Peripheral blood mononuclear cells: Isolation, freezing, thawing, and culture. Methods Mol Biol 2016; 1304: 53-61.
[http://dx.doi.org/10.1007/7651_2014_99] [PMID: 25092056]
[17]
Panda S, Ravindran B. In vitro Culture of Human PBMCs. Bio Protoc 2013; 3(3): e323..
[http://dx.doi.org/10.21769/BioProtoc.322]
[18]
Holzinger D, Jorns C, Stertz S, et al. Boisson-Dupuis S, Thimme R, Weidmann M, et al. Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol 2007; 81(14): 7776-85.
[http://dx.doi.org/10.1128/JVI.00546-06] [PMID: 17494065]
[19]
Fernández M, Quiroga JA, Martín J, et al. Herrero M, Pardo M, Horisberger MA, et al. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J Infect Dis 1999; 180(2): 262-7.
[http://dx.doi.org/10.1086/314859] [PMID: 10395838]
[20]
Delong RK, Zhou Q. Hexokinase and G6PDH catalyzed reactions of glucose measurement. n: Delong RK, Zhou Q, Eds.Introductory experiments on biomolecules and their Interactions. The Netherlands: Elsevier 2015; pp. 45-57.
[http://dx.doi.org/10.1016/B978-0-12-800969-7.00005-0]
[21]
Okasha H, Hassan M, Aboushousha T, Samir S. Effect of Interferon-Beta (IFN-β) on tumor suppressor and apoptotic markers in hepatocellular carcinoma cell line. Int J Res Pharm Sci 2019; 10(4): 2936-43.
[http://dx.doi.org/10.26452/ijrps.v10i4.1574]
[22]
Okasha H, Samir S. Synthesis and molecular cloning of antimicrobial peptide chromogranin A N-46 gene using conventional PCR. Gene Rep 2020; 18: 100571.
[http://dx.doi.org/10.1016/j.genrep.2019.100571]
[23]
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Δ Δ C(T)) method. Methods 2001; 25(4): 402-8.
[http://dx.doi.org/10.1006/meth.2001.1262] [PMID: 11846609]
[24]
Bertolotto A, Sala A, Caldano M, et al. , Capobianco M, Malucchi S, Marnetto F, et al. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 2007; 321(1-2): 19-31.
[http://dx.doi.org/10.1016/j.jim.2006.12.012] [PMID: 17335844]
[25]
Mozafari M, Tariverdian T, Beynaghi A. Trends in biotechnology at the turn of the millennium. Recent Pat Biotechnol 2020; 14(1): 78-82.
[http://dx.doi.org/10.2174/1872208313666190924162831] [PMID: 31549958]
[26]
Saxena SK, Mishra N, Saxena R. Advances in antiviral drug discovery and development: part II: Advancements in antiviral drug development. Future Virol 2009; 4(3): 209-15.
[http://dx.doi.org/10.2217/fvl.09.1]
[27]
Bernardes JS, Pedreira CE. A review of protein function prediction under machine learning perspective. Recent Pat Biotechnol 2013; 7(2): 122-41.
[http://dx.doi.org/10.2174/18722083113079990006] [PMID: 23848274]
[28]
Haller O, Staeheli P, Schwemmle M, Kochs G. Mx GTPases: dynamin-like antiviral machines of innate immunity. Trends Microbiol 2015; 23(3): 154-63.
[http://dx.doi.org/10.1016/j.tim.2014.12.003] [PMID: 25572883]
[29]
Gao XF, Yang ZW, Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int J Infect Dis 2011; 15(9): e594-600.
[http://dx.doi.org/10.1016/j.ijid.2011.05.002] [PMID: 21715206]
[30]
Lalle E, Calcaterra S, Horejsh D, et al. Abbate I, D’Offizi G, Abdeddaim A, et al. Ability of peripheral blood mononuclear cells to activate interferon response in vitro is predictive of virological response in HCV patients. J Biol Regul Homeost Agents 2008; 22(3): 153-60.
[PMID: 18842168]
[31]
Grossberg SE, Jameson PM, Sedmak JJ. "Assay of Interferons,"Berlin, Heidelberg: Springer 1984; pp. 23-43.
[32]
Abd El-Baky HH, El-Baroty GS. Spirulina maxima L-asparaginase: immobilization, antiviral and antiproliferation activities. Recent Pat Biotechnol 2020; 14(2): 154-63.
[http://dx.doi.org/10.2174/1872208313666191114151344] [PMID: 31724520]
[33]
Mire-Sluis AR, Gaines Das R, Zoon K, Padilla A, Thorpe R, Meager A. The biological properties, assay, and standardization of interferon-alpha: a need for a WHO collaborative study. J Interferon Cytokine Res 1996; 16(8): 637-43.
[http://dx.doi.org/10.1089/jir.1996.16.637] [PMID: 8877735]
[34]
Ronni T, Melén K, Malygin A, Julkunen I. “Control of IFN-inducible MxA gene expression in human cells.,” J Immunol 1993; 150(5): 1715-26.http://www.ncbi.nlm.nih.gov/pubmed/7679692
[35]
Ronni T, Sareneva T, Pirhonen J, Julkunen I. Activation of IFN-alpha, IFN-gamma, MxA, and IFN regulatory factor 1 genes in influenza A virus-infected human peripheral blood mononuclear cells. J Immunol 1995; 154(6): 2764-74.
[PMID: 7876547]
[36]
Raíssa CD. Recent Patents Applications in Red Biotechnology: a mini-review. Recent Pat Biotechnol 2019; 13(170): 170-86.
[37]
Goldsmith MA, You Y. Cell fusion assays for the identification of antiviral compounds, and systems and kits for practicing the same. US Patent 6,451,598., 2001.
[38]
Benjamin BJ. Dyall J, Jockel-Balsarotti J, O'Guin A, Olivo P, Roth R, et al. Method of discovery and development of broad-spectrum antiviral drugs. US Patent 10/766,226, 2004.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy